• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

对复发性尿路感染女童使用马尿酸乌洛托品进行长期预防。

Long-term prophylaxis with methenamine hippurate in girls with recurrent urinary tract infections.

作者信息

Petersen S

出版信息

Acta Paediatr Scand. 1978 Sep;67(5):597-9. doi: 10.1111/j.1651-2227.1978.tb17808.x.

DOI:10.1111/j.1651-2227.1978.tb17808.x
PMID:358737
Abstract

Twenty girls, aged 5-12 years, with recurrent urinary tract infections, were treated with methenamine hippurate, Hiprex, for a period of 12 months. The number of infections per patient per year was reduced from 3.1 to 0.7 (p less than 0.001). After prophylaxis was stopped this number increased to 1.4 which is a significantly higher incidence than occurred during treatment (p less than 0.05). A few girls complained of the taste but no side-effects were observed. Methenamine hippurate is a useful alternative in long-term prophylaxis against recurrent urinary tract infections in girls.

摘要

20名年龄在5至12岁之间、患有复发性尿路感染的女孩接受了马尿酸乌洛托品(商品名Hiprex)治疗,为期12个月。每位患者每年的感染次数从3.1次降至0.7次(p<0.001)。预防治疗停止后,这一数字增至1.4次,该发病率显著高于治疗期间(p<0.05)。少数女孩抱怨其味道,但未观察到副作用。马尿酸乌洛托品是长期预防女孩复发性尿路感染的一种有效替代药物。

相似文献

1
Long-term prophylaxis with methenamine hippurate in girls with recurrent urinary tract infections.对复发性尿路感染女童使用马尿酸乌洛托品进行长期预防。
Acta Paediatr Scand. 1978 Sep;67(5):597-9. doi: 10.1111/j.1651-2227.1978.tb17808.x.
2
Long-term treatment with methenamine hippurate in recurrent urinary tract infection.马尿酸乌洛托品用于复发性尿路感染的长期治疗。
Acta Med Scand. 1975 Jul-Aug;198(1-2):81-5. doi: 10.1111/j.0954-6820.1975.tb19508.x.
3
Secondary prevention of recurrent urinary tract infections. Comparison of the effect of placebo, methenamine hippurate, nitrofurantoin and trimethoprim alone.复发性尿路感染的二级预防。安慰剂、马尿酸乌洛托品、呋喃妥因和单独使用甲氧苄啶的效果比较。
Scand J Infect Dis. 1982;14(4):293-6. doi: 10.3109/inf.1982.14.issue-4.09.
4
[Clinical testing of methenamine hippurate (Hiprex) in the treatment of urinary tract infections].[马尿酸乌洛托品(希普力克斯)治疗尿路感染的临床试验]
Lakartidningen. 1973 Dec 5;70(49):4517-9.
5
Prevention of recurrent urinary infections in women: a comparative trial between nitrofurantoin and methenamine hippurate.女性复发性尿路感染的预防:呋喃妥因与马尿酸乌洛托品的对比试验
J Urol. 1981 Jul;126(1):71-4. doi: 10.1016/s0022-5347(17)54386-4.
6
Cost-effectiveness of methenamine hippurate compared with antibiotic prophylaxis for the management of recurrent urinary tract infections in secondary care: a multicentre, open-label, randomised, non-inferiority trial.马尿酸乌洛托品与抗生素预防疗法在二级保健中治疗复发性尿路感染的成本效益比较:一项多中心、开放标签、随机、非劣效性试验。
BMJ Open. 2024 Apr 29;14(4):e074445. doi: 10.1136/bmjopen-2023-074445.
7
[Methenamine hippurate. Short-term catheterization in gynecologic surgery. A double-blind comparison of Hiprex and placebo].[马尿酸乌洛托品。妇科手术中的短期导尿。希普雷克斯与安慰剂的双盲比较]
Tidsskr Nor Laegeforen. 1985 Mar 10;105(7):498-9.
8
Methenamine hippurate (Hiprex).马尿酸乌洛托品(希普力克斯)。
Med Lett Drugs Ther. 1968 Jul 26;10(15):58-60.
9
Methenamine hippurate compared with trimethoprim for the prevention of recurrent urinary tract infections: a randomized clinical trial.马尿酸乌洛托品与甲氧苄啶预防复发性尿路感染的比较:一项随机临床试验。
Int Urogynecol J. 2022 Mar;33(3):571-580. doi: 10.1007/s00192-021-04849-0. Epub 2021 Jun 11.
10
Controlled trial comparing co-trimoxazole and methenamine hippurate in the prevention of recurrent urinary tract infections.比较复方新诺明和马尿酸乌洛托品预防复发性尿路感染的对照试验。
Med J Aust. 1975 May 10;1(19):585-9.

引用本文的文献

1
Beware of formaldehyde in disguise.谨防伪装的甲醛。
Eur J Clin Pharmacol. 1982 Oct;23(4):373-5. doi: 10.1007/BF00613624.
2
Prevention of recurrent acute cystitis by methenamine hippurate: double blind controlled crossover long term study.马尿酸乌洛托品预防复发性急性膀胱炎:双盲对照交叉长期研究。
Br Med J (Clin Res Ed). 1987 Jun 13;294(6586):1507-8. doi: 10.1136/bmj.294.6586.1507.